Megabios: Adapting to a different reality

Megabios, which is developing cationic lipid-based systems for the in vivo delivery of genes and nucleic acids, is learning to respond quickly to customers' expectations, even if they are unexpected.

President and CEO Benjamin McGraw said Megabios originally planned to market its nonviral vectors to companies seeking single gene deals. But after four months and 24 company visits, Megabios discovered that companies were seeking "to lock down entire therapeutic areas" with vectors for multiple gene delivery.